Research Article
Poor Outcome and Mortality in Patients with Lower Lung-Dominant Sarcoidosis
Table 1
Baseline characteristics in patients with lower and nonlower lung-dominant sarcoidosis.
| | | Lower dominance
n = 11 | Nonlower dominance
n = 97 | value |
| | Age | 71 (62–73) | 56 (36–65) | 0.0005 | | Male/female | 8/3 (73%) | 34/63 (35%) | 0.0989 | | Smoking history | | CS/Ex/never | 0/7/4 | 23/22/52 | 0.3480 | | Extrapulmonary lesion, yes | 6 (55%) | 62 (64%) | 0.5315 | | Treatment | | Steroids/immunosuppressants | 5/2 | 4/0 | — | | ACE (U/L) | 22.4 (16.9–37.2) | 20.6 (15.2–25.7) | 0.0839 | | KL-6 (U/mL) | 1046 (699–2495) | 342 (232–447) | <0.0001 | | SP-D (ng/mL) | 193 (144–295) | 53.4 (31.5–80.0) | <0.0001 | | Ly% (BALF) | 29.4 (15.2–52.1) | 29.4 (19.2–45.4) | 0.6627 | | CD4/CD8 (BALF) | 6.30 (4.48–8.16) | 4.50 (2.65–7.55) | 0.2914 | | %FVC | 96.0 (63.5–108.7) | 103 (90.0–121) | 0.0220 | | %DLco | 63.2 (44.1–89.6) | 82.6 (69.6–93.5) | 0.0505 |
|
|
Values are n (%) or median (interquartile range). CS: current smokers; Ex: ex-smokers; never: never-smokers; ACE: angiotensin converting enzyme; KL-6: Krebs von Lungen-6; SP-D: surfactant protein-D, BALF: bronchoalveolar lavage fluid; FVC: forced vital capacity; DLco: diffusing capacity of carbon monoxide.
|
